Patents by Inventor Thibaud Biadatti

Thibaud Biadatti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof
    Patent number: 8765805
    Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: July 1, 2014
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Jean-Marie Arlabosse
  • Ligands that modulate RAR receptors
    Patent number: 8470871
    Abstract: Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: June 25, 2013
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Laurence Dumais, Catherine Soulet, Sandrine Talano, Sebastien Daver
  • Biphenyl compound selective agonists of gamma RAR receptors
    Patent number: 8362082
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: January 29, 2013
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Etienne Thoreau
  • NOVEL LIGANDS THAT MODULATE RAR RECEPTORS
    Publication number: 20120258996
    Abstract: Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 11, 2012
    Applicant: Galderma Research & Development
    Inventors: Thibaud BIADATTI, Laurence DUMAIS, Catherine SOULET, Sandrine TALANO, Sebastien DAVER
  • NOVEL LIGAND ACTIVATORS OF THE RAR RECEPTORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF
    Publication number: 20120214869
    Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.
    Type: Application
    Filed: April 30, 2012
    Publication date: August 23, 2012
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Thibaud BIADATTI, Jean-Marie Arlabosse
  • Ligands that modulate RAR receptors
    Patent number: 8227507
    Abstract: Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: July 24, 2012
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Laurence Dumais, Catherine Soulet, Sandrine Talano, Sebastien Daver
  • Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof
    Patent number: 8188106
    Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 29, 2012
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Jean-Marie Arlabosse
  • RAR receptor agonist ligands and use thereof in human medicine and cosmetics
    Patent number: 8163952
    Abstract: The invention relates to compounds corresponding to general formula (I) below: to the compositions containing same, to methods for the preparation thereof and to the use thereof in pharmaceutical compositions for use in human or veterinary medicine, or else in cosmetic compositions.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: April 24, 2012
    Assignee: Galderma Research & Development
    Inventor: Thibaud Biadatti-Portal
  • Biphenyl compound selective agonists of gamma RAR receptors
    Patent number: 8106235
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: January 31, 2012
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Etienne Thoreau
  • BIPHENYL COMPOUND SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS
    Publication number: 20120016031
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 19, 2012
    Applicant: GALDERMA Research & Development
    Inventors: Thibaud BIADATTI, Etienne Thoreau
  • Biphenyl compound selective agonists of gamma RAR receptors
    Patent number: 8049034
    Abstract: Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: November 1, 2011
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Etienne Thoreau
  • Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof
    Patent number: 7872026
    Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radical of formulae (a) to (c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively, into cosmetic compositions.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: January 18, 2011
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Olivier Roye
  • NOVEL LIGANDS THAT MODULATE RAR RECEPTORS
    Publication number: 20100292296
    Abstract: Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
    Type: Application
    Filed: July 23, 2010
    Publication date: November 18, 2010
    Applicant: Galderma Research & Development
    Inventors: Thibaud BIADATTI, Laurence Dumais, Catherine Soulet, Sandrine Talano, Sebastien Daver
  • Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof
    Publication number: 20100273883
    Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.
    Type: Application
    Filed: July 6, 2010
    Publication date: October 28, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventors: Thibaud Biadatti, Jean-Marie Arlabosse
  • NOVEL RAR RECEPTOR AGONIST LIGANDS AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS
    Publication number: 20100261754
    Abstract: The invention relates to compounds corresponding to general formula (I) below: to the compositions containing same, to methods for the preparation thereof and to the use thereof in pharmaceutical compositions for use in human or veterinary medicine, or else in cosmetic compositions.
    Type: Application
    Filed: April 24, 2008
    Publication date: October 14, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Thibaud Biadatti-Portal
  • Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
    Patent number: 7807708
    Abstract: Novel ligand compounds having the general formula (I): and pharmaceutical/cosmetic compositions comprised thereof are useful in human and veterinary medicine or, alternatively, in cosmetics.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: October 5, 2010
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Laurence Dumais, Catherine Soulet, Sandrine Talano, Sebastien Daver
  • Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof
    Patent number: 7767650
    Abstract: Novel ligand compounds having the structural formula (I): in which: Ar is a radical selected from among the radicals of formulae (a)-(c) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine, or, alternatively into cosmetic compositions.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: August 3, 2010
    Assignee: Galderma Research & Development
    Inventors: Thibaud Biadatti, Jean-Marie Arlabosse
  • Pactimibe medicaments for preventing/treating a disease due to sebaceous gland dysfunction in humans or animals
    Publication number: 20100179209
    Abstract: Administration of at least one compound selected from N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (pactimibe) of formula (I): or pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, is useful for preventing or treating a disorder due to a sebaceous gland dysfunction in humans or animals, for example acne and/or any state or pathological condition related to an overproduction of sebum, e.g., seborrhoeic dermatitis, greasy skin or a greasy scalp.
    Type: Application
    Filed: January 15, 2010
    Publication date: July 15, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Thibaud BIADATTI-PORTAL
  • EFLUCIMIBE MEDICAMENTS FOR PREVENTING/TREATING A DISEASE DUE TO SEBACEOUS GLAND DYSFUNCTION IN HUMANS OR ANIMALS
    Publication number: 20100172957
    Abstract: Administration of at least one compound selected from (S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetanilide (eflucimibe) of formula (I): or (R)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetanilide ((R) enantiomer), or pharmaceutically acceptable salt or pharmaceutically acceptable solvate thereof, is useful for preventing or treating disorders due to a sebaceous gland dysfunction in humans or animals, for example, acne and/or or any state or pathological condition related to an overproduction of sebum, e.g., seborrhoeic dermatitis, greasy skin or a greasy scalp.
    Type: Application
    Filed: January 15, 2010
    Publication date: July 8, 2010
    Applicant: GALDERMA RESEARCH & DEVELOPMENT
    Inventor: Thibaud BIADATTI-PORTAL
  • Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof
    Patent number: 7592478
    Abstract: Novel ligand antagonists of the RAR receptors have the following structural formula (I): in which A is a CH2, CHOH, C?O or C?N—OH radical or a sulfur or selenium atom; B is a radical selected from among those of formulae (a) to (f): and Ar is a radical selected from among those of formulae (g) to (i):
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: September 22, 2009
    Assignee: Galderma Research & Development
    Inventors: Philippe Diaz, Catherine Raffin, Thibaud Biadatti